Status:
UNKNOWN
Outcome Analysis of Aspirin in Liver Transplantation
Lead Sponsor:
University of Zurich
Conditions:
Liver Transplant; Complications
Eligibility:
All Genders
18+ years
Brief Summary
In the experimental setting inhibition of platelet activation was able to reduce immune-mediated necroinflammatory liver disease and consecutively hepatocellular carcinoma development. Therefore, anti...
Detailed Description
Outcome Analysis of antiplatelet therapy with Aspirin in Liver Transplantation BACKGROUND Arterial complications after liver transplantation (LT) are still one of the most serious complications, whic...
Eligibility Criteria
Inclusion
- Adult Liver transplantation(age ≥18 years)
- Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)
- Primary liver transplantation, whole graft
- Arterial anastomosis: end-to-end, back table reconstruction
Exclusion
- Split liver and living donor liver transplantation
- Paediatric liver transplantation (recipient age \<18 years)
- Arterial conduits
- Multivisceral transplantations
- Retransplantations
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2021
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT04327427
Start Date
October 1 2019
End Date
May 31 2021
Last Update
March 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Visceral and Transplantation Surgery
Zurich, CH/Zürich, Switzerland, 8091